Patient-derived xenograft (PDX) models are valuable platforms to assess preclinical and clinical trials for cancer therapy including lung cancer. The authors clarified that enriched expression of immune system-associated genes such as CD19 and CD23 are the most critical factors to obstacle the PDX generation, particularly in lung squamous cell carcinoma.
- Yunjung Kim
- Aya Shiba-Ishii
- Noriaki Sakamoto
